Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms Publisher



Karami Fath M¹ ; Babakhaniyan K² ; Anjomrooz M³ ; Jalalifar M⁴ ; Alizadeh SD⁴ ; Pourghasem Z⁵ ; Abbasi Oshagh P⁶ ; Azargoonjahromi A⁷ ; Almasi F⁸ ; Manzoor HZ⁹ ; Khalesi B¹⁰ ; Pourzardosht N¹¹ ; Khalili S¹² ; Payandeh Z¹³
Source: Vaccines Published:2022

Abstract

Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations. © 2022 by the authors.